Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats

European Neuropsychopharmacology

Volumn 22, Issue 4, 2012, Pages 290-299

  Van de Giessen, Elsmarieke ^a   de Bruin, Kora ^a   la Fleur, Susanne E ^a   van den Brink, Wim ^b   Booij, Jan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

Diet induced obesity; Dopamine D2 receptor; Food intake; Striatum; Tesofensine

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; TESOFENSINE;

ARTICLE; BODY WEIGHT; CALORIC INTAKE; CORPUS STRIATUM; DIET; DRUG EFFECT; FOOD INTAKE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; PRIORITY JOURNAL; RAT; WEIGHT GAIN; WISTAR RAT;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BODY WEIGHT; CORPUS STRIATUM; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EATING; ENERGY INTAKE; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NUCLEUS ACCUMBENS; OBESITY; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84857235048     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.07.015     Document Type: Article

References (37)

1. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl.) 1998, 140:470-477.
2. Astrup A., Madsbad S., Breum L., Jensen T.J., Kroustrup J.P., Larsen T.M. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1906-1913.
3. Avena N.M., Rada P., Hoebel B.G. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci. Biobehav. Rev. 2008, 32:20-39.
4. Axel A.M., Mikkelsen J.D., Hansen H.H. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010, 35:1464-1476.
5. Bassareo V., Di Chiara G. Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments. Neuroscience 1999, 89:637-641.
6. Billes S.K., Cowley M.A. Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 2008, 33:1287-1297.
7. Booze R.M., Wallace D.R. Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse 1995, 19:1-13.
8. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991, 564:203-219.
9. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de B A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2569-2574.
10. Cailotto C., La Fleur S.E., Van Heijningen C., Wortel J., Kalsbeek A., Feenstra M., Pévet P., Buijs R.M. The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: are the clock genes involved?. Eur. Neurosci. 2005, 22:2531-2540.
11. Cooper S.J., Al-Naser H.A. Dopaminergic control of food choice: contrasting effects of SKF 38393 and quinpirole on high-palatability food preference in the rat. Neuropharmacology 2006, 50:953-963.
12. Crunelle C.L., Miller M.L., de Bruin K., van den Brink W., Booij J. Varenicline increases striatal dopamine D(2/3) receptor binding in rats. Addict. Biol. 2009, 14:500-502.
13. Davis L.M., Michaelides M., Cheskin L.J., Moran T.H., Aja S., Watkins P.A., Pei Z., Contoreggi C., McCullough K., Hope B., Wang G.J., Volkow N.D., Thanos P.K. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology 2009, 89:152-162.
14. Dziedzicka-Wasylewska M., Rogoz R., Klimek V., Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J. Neural. Transm. 1997, 104:515-524.
15. Dziedzicka-Wasylewska M., Rogoz Z., Skuza G., Dlaboga D., Maj J. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2)/D(3) receptors. Behav. Pharmacol. 2002, 13:127-138.
16. Hajnal A., Margas W.M., Covasa M. Altered dopamine D2 receptor function and binding in obese OLETF rat. Brain Res. Bull. 2008, 75:70-76.
17. Hamdi A., Porter J., Prasad C. Decreased striatal D2 dopamine receptors in obese Zucker rats: changes during aging. Brain Res. 1992, 589:338-340.
18. Hansen H.H., Hansen G., Tang-Christensen M., Larsen P.J., Axel A.M., Raben A., Mikkelsen J.D. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur. J. Pharmacol. 2010, 636:88-95.
19. Huang X.F., Zavitsanou K., Huang X., Yu Y., Wang H., Chen F., Lawrence A.J., Deng C. Dopamine transporter and D2 receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity. Behav. Brain Res. 2006, 175:415-419.
20. Johnson P.M., Kenny P.J. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat. Neurosci. 2010, 13:635-641.
21. Jongen C., de Bruin K., Beekman F., Booij J. SPECT imaging of D2 dopamine receptors and endogenous dopamine release in mice. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1692-1698.
22. Kameda K., Kusumi I., Suzuki K., Miura J., Sasaki Y., Koyama T. Effects of citalopram on dopamine D2 receptor expression in the rat brain striatum. J. Mol. Neurosci. 2000, 14:77-86.
23. Knol R.J., de Bruin K., de Jong J., van Eck-Smit B.L., Booij J. In vitro and ex vivo storage phosphor imaging of short-living radioisotopes. J. Neurosci. Methods 2008, 168:341-357.
24. La Fleur S.E., van Rozen A.J., Luijendijk M.C., Groeneweg F., Adan R.A. A free-choice high-fat high-sugar diet induces changes in arcuate neuropeptide expression that support hyperphagia. Int. J. Obes. (Lond.) 2010, 34:537-546.
25. Mercer J.G., Archer Z.A. Putting the diet back into diet-induced obesity: diet-induced hypothalamic gene expression. Eur. J. Pharmacol. 2008, 585:31-37.
26. Nelson D.L., Gehlert D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006, 29:49-60.
27. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 116B:103-125.
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney, Australia.
29. Schoedel K.A., Meier D., Chakraborty B., Manniche P.M., Sellers E.M. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin. Pharmacol. Ther. 2010, 88:69-78.
30. Sjodin A., Gasteyger C., Nielsen A.L., Raben A., Mikkelsen J.D., Jensen J.K., Meier D., Astrup A. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int. J. Obes. (Lond.) 2010, 34:1634-1643.
31. Thanos P.K., Michaelides M., Piyis Y.K., Wang G.J., Volkow N.D. Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in-vivo muPET imaging ([11C] raclopride) and in-vitro ([3H] spiperone) autoradiography. Synapse 2008, 62:50-61.
32. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997, 7:479-484.
33. Verhoeff N.P., Bobeldijk M., Feenstra M.G., Boer G.J., Maas M.A., Erdtsieck-Ernste E., de Bruin K., van Royen E.A. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain. Int. J. Rad. Appl. Instrum. B 1991, 18:837-846.
34. Verhoeff N.P., Kapucu O., Sokole-Busemann E., van Royen E.A., Janssen A.G. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J. Nucl. Med. 1993, 34:2076-2084.
35. Volkow N.D., Wise R.A. How can drug addiction help us understand obesity?. Nat. Neurosci. 2005, 8:555-560.
36. Volkow N.D., Fowler J.S., Wang G.J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J. Psychopharmacol. 1999, 13:337-345.
37. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., Fowler J.S. Brain dopamine and obesity. Lancet 2001, 357:354-357.